| UniProt/SwissProt ID: | HSPB1_HUMAN |
| Description: | heat shock 27kDa protein 1 [Source:HGNC Symbol;Acc:5246] |
| Location: | chr7 q11.23 |
| Node attribute: | ubiquitination(source); substrate; gene |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| S82 | LSRQLsSGVSE | PKD1 | phosphoELM; RegPhos |
| S86 | LSSGVsEIRHT | PhosphoSitePlus; HPRD; phosphoELM; RegPhos | |
| T174 | MPKLAtQSNEI | HPRD | |
| S199 | PEAAKsDETAA | PhosphoSitePlus | |
| S74 | AAPAYsRALSR | PhosphoSitePlus | |
| S78 | YSRALsRQLSS | MAPKAPK2 | HPRD; phosphoELM; RegPhos |
| S65 | PAAIEsPAVAA | PhosphoSitePlus; HPRD; phosphoELM; RegPhos | |
| S199 | PEAAKsDETA | HPRD; phosphoELM | |
| S78 | YSRALsRQLSS | p70S6Kb | phosphoELM; RegPhos |
| T143 | FTRKYtLPPGV | HSP20 | PhosphoSitePlus |
| S83 | SRQLSsGVSEI | PhosphoSitePlus; HPRD; phosphoELM; RegPhos | |
| S82 | LSRQLsSGVSE | AKT_group | RegPhos |
| Y54 | SSWPGyVRPLP | PhosphoSitePlus | |
| T91 | SEIRHtADRWR | phosphoELM; RegPhos | |
| T113 | ELTVKtKDGVV | HPRD | |
| S176 | KLATQsNEITI | HSP20 | PhosphoSitePlus |
| S98 | DRWRVsLDVNH | HSP20; YabP | PhosphoSitePlus |
| T113 | ELTVKtKDGVV | HSP20; YabP | PhosphoSitePlus |
| S15 | LLRGPsWDPFR | MAPKAPK2 | HPRD; phosphoELM; RegPhos |
| S15 | LLRGPsWDPFR | MAPKAPK3 | HPRD; RegPhos |
| S15 | LLRGPsWDPFR | PhosphoSitePlus; HPRD; phosphoELM; RegPhos | |
| S82 | LSRQLsSGVSE | PhosphoSitePlus; HPRD; phosphoELM; RegPhos | |
| Y73 | VAAPAySRALS | PhosphoSitePlus | |
| S135 | EHGYIsRCFTR | HSP20 | PhosphoSitePlus |
| T174 | MPKLAtQSNEI | HSP20 | PhosphoSitePlus |
| Y142 | CFTRKyTLPPG | HSP20 | PhosphoSitePlus |
| S82 | LSRQLsSGVSE | MAPKAPK2 | HPRD; phosphoELM; RegPhos |
| S82 | LSRQLsSGVSE | MAPKAPK3 | HPRD; RegPhos |
| Y133 | QDEHGyISRCF | HSP20 | PhosphoSitePlus |
| Y23 | PFRDWyPHSRL | PhosphoSitePlus | |
| S82 | LSRQLsSGVSE | p70S6Kb | phosphoELM; RegPhos |
| T110 | APDELtVKTKD | HPRD | |
| S78 | YSRALsRQLSS | MAPKAPK3 | HPRD; RegPhos |
| S78 | YSRALsRQLSS | PhosphoSitePlus; HPRD; phosphoELM; RegPhos | |
| T121 | GVVEItGKHEE | HSP20; YabP | PhosphoSitePlus |
| S15 | LLRGPsWDPFR | PKA_group | RegPhos |
| S98 | DRWRVsLDVNH | HPRD | |
| S9 | RRVPFsLLRGP | PhosphoSitePlus | |
| T121 | GVVEItGKHEE | HPRD | |
| T139 | ISRCFtRKYTL | HSP20 | PhosphoSitePlus |
| S135 | EHGYIsRCFTR | HPRD | |
| S26 | DWYPHsRLFDQ | HPRD; RegPhos | |
| Dephosphorylation site |
| HSPB1_HUMAN do not have dephosphorylation site. |
| Mutation site |
| HSPB1_HUMAN do not have mutation site. |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000248553 | Non-small cell lung carcinoma | Metastasis | cell line | Down | 17537172 | ENSP00000248553 | Hepatocellular Carcinoma | Normal vs. Cancer | cell line | Down | 0.45 | 18646787 | ENSP00000248553 | Hepatocellular Carcinoma | Normal vs. Cancer | cell line | Up | 2.6 | 18646787 | ENSP00000248553 | Breast Cancer | Metastasis | cell line | Up | 16637015 | ENSP00000248553 | Prostate Cancer | Metastasis | cell line | Down | 0.33 | 15102926 | ENSP00000248553 | Hepatocellular Carcinoma | Normal vs. Cancer | tissue | Up | 3.8 | 15759316 | ENSP00000248553 | Breast Cancer | Metastasis | cell line | Up | 5.5 | 16048908 | ENSP00000248553 | Thyroid Carcinoma | Normal vs. Cancer | tissue | Up | 2.6 | 17194741 | ENSP00000248553 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 1.2 | 19072117 | ENSP00000248553 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 1.9 | 19072117 | ENSP00000248553 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Down | 0.78 | 19072117 | ENSP00000248553 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 1.3 | 19072117 | ENSP00000248553 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 1.1 | 19072117 | ENSP00000248553 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 2.4 | 19072117 | ENSP00000248553 | Esophageal Cancer | Normal vs. Cancer | tissue | Down | 0.46 | 19142970 | ENSP00000248553 | Oral Cancer | Normal vs. Cancer | tissue | Up | 4.3 | 16889763 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | tissue | Up | 12687611 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Up | 2 | 14997480 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | tissue | Up | 8 | 16470630 | ENSP00000248553 | Breast Cancer | Treatment (none vs. multidrug resistant) | cell line | Up | 1.6 | 16540677 | ENSP00000248553 | Breast Cancer | Metastasis | cell line | Up | 16637015 | ENSP00000248553 | Melanoma | Treatment (none vs. metastasis suppressor 1 (BRMS1) overEXPressed) | cell line | Down | 0.51 | 17854218 | ENSP00000248553 | Melanoma | Treatment (none vs. metastasis suppressor 1 (BRMS1) silenced) | cell line | Up | 1.7 | 17854218 | ENSP00000248553 | hepatitis B virus | Normal vs. Cancer | tissue | Down | 0.052 | 14654528 | ENSP00000248553 | hepatitis C virus | Normal vs. Cancer | tissue | Up | 4.4 | 14654528 | ENSP00000248553 | Hepatocellular Carcinoma | Normal vs. Cancer | tissue | Up | 2.7 | 14654528 | ENSP00000248553 | hepatitis B virus | Normal vs. Cancer | tissue | Up | 16240287 | ENSP00000248553 | Hepatocellular Carcinoma | Normal vs. Cancer | tissue | Up | 16240287 | ENSP00000248553 | Hepatocellular Carcinoma | Treatment (none vs. Suberonylanilide hydroxamic acid (SAHA) treatment) | tissue | Down | 17593366 | ENSP00000248553 | hepatitis B virus | Normal vs. Cancer | tissue | Up | 2.2 | 17671684 | ENSP00000248553 | Neoplasms by Histologic Type | Normal vs. Cancer | tissue | Up | 4 | 12874873 | ENSP00000248553 | Small cell lung carcinoma | Treatment(none vs paclitaxel treatment) | tissue | Down | 15152945 | ENSP00000248553 | Non-small cell lung carcinoma | Metastasis | cell line | Down | 0.31 | 17418446 | ENSP00000248553 | Non-small cell lung carcinoma | Treatment (none vs CIGB-300 treatment) | cell line | Down | 0.3 | 20804217 | ENSP00000248553 | Gastric Cancer | Treatment (none vs. Vincristine-resistant) | cell line | Up | 16525997 | ENSP00000248553 | Gastric Cancer | Treatment (none vs. Vincristine-resistant) | cell line | Up | 3.8 | 18253933 | ENSP00000248553 | Breast Cancer | Metastasis | cell line | Up | 3.4 | 18582095 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Up | 2.4 | 20052998 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Up | 3.4 | 20052998 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.35 | 20052998 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.67 | 20052998 | ENSP00000248553 | Breast Cancer | Metastasis | cell line | Down | 0.15 | 20052998 | ENSP00000248553 | Breast Cancer | Metastasis | cell line | Down | 0.2 | 20052998 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Up | 4.2 | 20052998 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Up | 7.6 | 20052998 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Up | 8 | 20052998 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.22 | 20052998 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.27 | 20052998 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.31 | 20052998 | ENSP00000248553 | Breast Cancer | Metastasis | cell line | Down | 0.035 | 20052998 | ENSP00000248553 | Breast Cancer | Metastasis | cell line | Down | 0.038 | 20052998 | ENSP00000248553 | Breast Cancer | Metastasis | cell line | Down | 0.053 | 20052998 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.75 | 20543960 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | tissue | Up | 0.57 | 20739354 | ENSP00000248553 | Breast Cancer | Normal vs. Cancer | tissue | Up | 0.57 | 20739354 | ENSP00000248553 | Oral Cancer | Normal vs. Cancer | tissue | Up | 5.6 | 19691830 | ENSP00000248553 | chronic myeloid leukemia | Treatment (Imatinib-sensitive vs. Imatinib-resistant) | cell line | Down | 20417730 | ENSP00000248553 | Leukemia | Cancer vs. Cancer (subtype) | tissue | Up | 15501966 | ENSP00000248553 | Testicular Cancer | Normal vs. Cancer | cell line | Up | 18489135 | ENSP00000248553 | Ovarian Cancer | Normal vs. Cancer | cell line | Down | 0.59 | 15591324 | ENSP00000248553 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.67 | 19714814 | ENSP00000248553 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Up | 1.5 | 19714814 | ENSP00000248553 | Pancreatic Cancer | Normal vs. Cancer | tissue | Down | 0.2 | 15526344 | ENSP00000248553 | Gastric Cancer | Treatment (none vs. drug-resistant) | cell line | Up | 2.7 | 20625496 | ENSP00000248553 | Gastric Cancer | Normal vs. Cancer | tissue | Up | 20677338 | ENSP00000248553 | Uterine Cancer | Normal vs. Cancer | tissue | Up | 16051329 | ENSP00000248553 | Uterine Cancer | Cancer vs. Cancer | cell line | Up | 17616526 | ENSP00000248553 | Uterine Cancer | Treatment (none vs. Suberonylanilide hydroxamic acid (SAHA) treatment) | cell line | Down | 19179759 | ENSP00000248553 | Uterine Cancer | Normal vs. Cancer | tissue | Up | 19771267 | ENSP00000248553 | pancreatic ductal adenocarcinoma | Normal vs. Cancer | tissue | Up | 17492507 | ENSP00000248553 | Pancreatic Cancer | Treatment (Gemcitabine-sensitive vs. Gemcitabine-resistant) | cell line | Up | 3 | 20944110 | ENSP00000248553 | Pancreatic Cancer | Treatment (Gemcitabine-sensitive vs. Gemcitabine-resistant) | cell line | Up | 3.3 | 20944110 |
| Hyperphosphorylation site |
| Site | Motif | Peptide | Cancer name | Pubmed | Source |
|---|---|---|---|---|---|
| S82 | RALSRQLsSGVSEIR | atherosclerosis | 15249501 | PhosphoSitePlus | S78 | PAYSRALsRQLSSGV | breast cancer | 17697330 | PhosphoSitePlus |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| MAPK2_HUMAN | HSPB1_HUMAN | kinase -> substrate | RegPhos |
| PKD1_HUMAN | HSPB1_HUMAN | kinase -> substrate | RegPhos |
| ZAGL2_HUMAN | HSPB1_HUMAN | kinase -> substrate | RegPhos |
| NEK3_HUMAN | HSPB1_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| KS6B2_HUMAN | HSPB1_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| MAPK3_HUMAN | HSPB1_HUMAN | kinase -> substrate | RegPhos |
| TBK1_HUMAN | HSPB1_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| MAPK5_HUMAN | HSPB1_HUMAN | kinase -> substrate | KEGG |
| HSPB1_HUMAN | IKBA_HUMAN | ubiquitination | NetPath |
| SP1_HUMAN | HSPB1_HUMAN | TF -> target gene | TRANSFAC |
| AHR_HUMAN | HSPB1_HUMAN | TF -> target gene | TRANSFAC |
| AP2A_HUMAN | HSPB1_HUMAN | TF -> target gene | TRANSFAC |
| Function Annotation |
| KEGG Pathway |
| KEGG ID | Pathway |
|---|---|
| hsa04370 | VEGF signaling pathway |
| hsa05169 | Epstein-Barr virus infection |
| hsa05146 | Amoebiasis |
| hsa04010 | MAPK signaling pathway |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:2001028 | positive regulation of endothelial cell chemotaxis | IMP | biological_process |
| GO:0005737 | cytoplasm | TAS | cellular_component |
| GO:0006469 | negative regulation of protein kinase activity | ISS | biological_process |
| GO:0009986 | cell surface | IDA | cellular_component |
| GO:0009615 | response to virus | IEP | biological_process |
| GO:0005515 | protein binding | IPI | molecular_function |
| GO:0005622 | intracellular | IEA | cellular_component |
| GO:0043130 | ubiquitin binding | ISS | molecular_function |
| GO:0043122 | regulation of I-kappaB kinase/NF-kappaB cascade | IEA | biological_process |
| GO:0019901 | protein kinase binding | IPI | molecular_function |
| GO:0030018 | Z disc | IEA | cellular_component |
| GO:0005829 | cytosol | TAS | cellular_component |
| GO:0008219 | cell death | IEA | biological_process |
| GO:0005819 | spindle | IEA | cellular_component |
| GO:0038033 | positive regulation of endothelial cell chemotaxis | IMP | biological_process |
| GO:0006928 | cellular component movement | TAS | biological_process |
| GO:0045766 | positive regulation of angiogenesis | IMP | biological_process |
| GO:0005737 | cytoplasm | IEA | cellular_component |
| GO:0016070 | RNA metabolic process | TAS | biological_process |
| GO:0005080 | protein kinase C binding | IEA | molecular_function |
| GO:0007243 | intracellular protein kinase cascade | IMP | biological_process |
| GO:0032731 | positive regulation of interleukin-1 beta producti | IEA | biological_process |
| GO:0006469 | negative regulation of protein kinase activity | IEA | biological_process |
| GO:0016071 | mRNA metabolic process | TAS | biological_process |
| GO:0005856 | cytoskeleton | TAS | cellular_component |
| GO:0005886 | plasma membrane | IEA | cellular_component |
| GO:0008426 | protein kinase C inhibitor activity | IEA | molecular_function |
| GO:0043292 | contractile fiber | IEA | cellular_component |
| GO:0005634 | nucleus | IEA | cellular_component |
| GO:0006446 | regulation of translational initiation | TAS | biological_process |
| GO:0010467 | gene expression | TAS | biological_process |
| GO:0042535 | positive regulation of tumor necrosis factor biosy | IEA | biological_process |
| GO:0006986 | response to unfolded protein | NAS | biological_process |
| GO:0043066 | negative regulation of apoptotic process | IEA | biological_process |
| GO:0035924 | cellular response to vascular endothelial growth f | IMP | biological_process |
| GO:0043536 | positive regulation of blood vessel endothelial ce | IMP | biological_process |
| GO:0000502 | proteasome complex | ISS | cellular_component |